Claims for Patent: 10,519,187

Summary for Patent: 10,519,187

Title:	Cyclic dinucleotides as anticancer agents
Abstract:	The present invention is directed to compounds of the formulae I, II and III as shown below ##STR00001## wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
Inventor(s):	Fink; Brian E. (Yardley, PA), Dodd; Dharmpal S. (Monmouth Junction, NJ), Walker; Steven J. (Portage, MI), Chen; Libing (Newtown, PA), Zhao; Yufen (Pennington, NJ), Ruan; Zheming (Dayton, NJ), Qin; Lan-Ying (Plainsboro, NJ), Park; Peter Kinam (New York, NY), Kamau; Muthoni G. (Lawrenceville, NJ), Harikrishnan; Lalgudi S. (Skillman, NJ)
Assignee:	Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:	16/272,172
Patent Claims:	1. A compound of formula I ##STR00419## wherein X is independently O or S; X.sup.1, X.sup.2, X.sup.3 and X.sup.4 are each independently O or NH; R.sup.1 and R.sup.2 are independently ##STR00420## with the proviso that one of R.sup.1 and R.sup.2 must be ##STR00421## Z.sub.1 is N or CR.sup.a; Z.sub.2 is NR.sup.b; R.sup.a is H, halogen, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.b is H, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, --C(O)R.sup.a1, --C(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.a1 is H, C.sub.1-3 alkyl or C.sub.3-6 cycloalkyl; R.sup.3 is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; R.sup.3a is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; or R.sup.3 and R.sup.3a may be taken together to form a 3-4 membered carbocycle; or R.sup.3 and R.sup.3a may be taken together to form a C.dbd.CH.sub.2 substituent; R.sup.5 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; or two R.sup.5 groups may be taken together to form a 5-6 membered carbocyclic or heterocyclic group; or R.sup.5 and R.sup.6 may be taken together to form a 5-6 membered carbocyclic or heterocyclic group; R.sup.5a is H or C.sub.1-3 alkyl; R.sup.6 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.8 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.9 is H, halogen or methyl; Y is CR.sup.a or N; m is 0, 1, 2 or 3; n is 0 or 1; or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. 2. The compound according to claim 1 of formula I ##STR00422## wherein X is S; X.sup.1, X.sup.2, X.sup.3 and X.sup.4 are each independently O or NH; R.sup.1 and R.sup.2 are independently ##STR00423## with the proviso that one of R.sup.1 and R.sup.2 must be ##STR00424## Z.sub.1 is N or CR.sup.a; Z.sub.2 is NR.sup.b; R.sup.a is H, halogen, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.b is H, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, --C(O)R.sup.a1, --C(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.a1 is H, C.sub.1-3 alkyl or C.sub.3-6 cycloalkyl; R.sup.3 is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; R.sup.3a is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; or R.sup.3 and R.sup.3a may be taken together to form a 3-4 membered carbocycle; or R.sup.3 and R.sup.3a may be taken together to form a C.dbd.CH.sub.2 substituent; R.sup.5 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.5a is H or C.sub.1-3 alkyl; R.sup.6 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.8 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.9 is H, halogen or methyl; Y is CR.sup.a or N; m is 0, 1, 2 or 3; n is 0 or 1; or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. 3. The compound according to claim 1 of formula I ##STR00425## wherein X is O; X.sup.1, X.sup.2, X.sup.3 and X.sup.4 are each independently O or NH; R.sup.1 and R.sup.2 are independently ##STR00426## with the proviso that one of R.sup.1 and R.sup.2 must be ##STR00427## Z.sub.1 is N or CR.sup.a; Z.sub.2 is NR.sup.b; R.sup.a is H, halogen, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.b is H, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, --C(O)R.sup.a1, --C(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.a1 is H, C.sub.1-3 alkyl or C.sub.3-6 cycloalkyl; R.sup.3 is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; R.sup.3a is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; or R.sup.3 and R.sup.3a may be taken together to form a 3-4 membered carbocycle; or R.sup.3 and R.sup.3a may be taken together to form a C.dbd.CH.sub.2 substituent; R.sup.5 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.5a is H or C.sub.1-3 alkyl; R.sup.6 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.8 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.9 is H, halogen or methyl; Y is CR.sup.a or N; m is 0, 1, 2 or 3; n is 0 or 1; or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. 4. The compound according to claim 1 of the formula ##STR00428## wherein X.sup.1, X.sup.2, X.sup.3 and X.sup.4 are each independently O or NH; R.sup.1 and R.sup.2 are independently ##STR00429## with the proviso that one of R.sup.1 and R.sup.2 must be ##STR00430## Z.sub.1 is N or CR.sup.a; Z.sub.2 is NR.sup.b; R.sup.a is H, halogen, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.b is H, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, --C(O)R.sup.a1, --C(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.a1 is H, C.sub.1-3 alkyl or C.sub.3-6 cycloalkyl; R.sup.3 is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; R.sup.3a is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; or R.sup.3 and R.sup.3a may be taken together to form a 3-4 membered carbocycle; or R.sup.3 and R.sup.3a may be taken together to form a C.dbd.CH.sub.2 substituent; R.sup.5 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.5a is H or C.sub.1-3 alkyl; R.sup.6 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.8 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.9 is H, halogen or methyl; Y is CR.sup.a or N; m is 0, 1, 2 or 3; n is 0 or 1; or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. 5. The compound according to claim 1 of the formula ##STR00431## wherein X.sup.1, X.sup.2, X.sup.3 and X.sup.4 are each independently O or NH; R.sup.1 and R.sup.2 are independently ##STR00432## with the proviso that one of R.sup.1 and R.sup.2 must be ##STR00433## Z.sub.1 is N or CR.sup.a; Z.sub.2 is NR.sup.b; R.sup.a is H, halogen, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.b is H, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, --C(O)R.sup.a1, --C(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.a1 is H, C.sub.1-3 alkyl or C.sub.3-6 cycloalkyl; R.sup.3 is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; R.sup.3a is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; or R.sup.3 and R.sup.3a may be taken together to form a 3-4 membered carbocycle; or R.sup.3 and R.sup.3a may be taken together to form a C.dbd.CH.sub.2 substituent; R.sup.5 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.5a is H or C.sub.1-3 alkyl; R.sup.6 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.8 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.9 is H, halogen or methyl; Y is CR.sup.a or N; m is 0, 1, 2 or 3; n is 0 or 1; or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. 6. The compound according to claim 1 of the formula ##STR00434## wherein X is independently O or S; R.sup.1 and R.sup.2 are independently ##STR00435## with the proviso that one of R.sup.1 and R.sup.2 must be ##STR00436## Z.sub.1 is N or CR.sup.a; Z.sub.2 is NR.sup.b; R.sup.a is H, halogen, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.b is H, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, --C(O)R.sup.a1, --C(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.a1 is H, C.sub.1-3 alkyl or C.sub.3-6 cycloalkyl; R.sup.3 is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; R.sup.3a is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; or R.sup.3 and R.sup.3a may be taken together to form a 3-4 membered carbocycle; or R.sup.3 and R.sup.3a may be taken together to form a C.dbd.CH.sub.2 substituent; R.sup.5 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.5a is H or C.sub.1-3 alkyl; R.sup.6 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.8 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.9 is H, halogen or methyl; Y is CR.sup.a or N; m is 0, 1, 2 or 3; n is 0 or 1; or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. 7. The compound according to claim 1 of the formula ##STR00437## wherein X is S; R.sup.1 and R.sup.2 are independently ##STR00438## with the proviso that one of R.sup.1 and R.sup.2 must be ##STR00439## Z.sub.1 is N or CR.sup.a; Z.sub.2 is NR.sup.b; R.sup.a is H, halogen, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.b is H, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, --C(O)R.sup.a1, --C(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.a1 is H, C.sub.1-3 alkyl or C.sub.3-6 cycloalkyl; R.sup.3 is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; R.sup.3a is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; or R.sup.3 and R.sup.3a may be taken together to form a 3-4 membered carbocycle; or R.sup.3 and R.sup.3a may be taken together to form a C.dbd.CH.sub.2 substituent; R.sup.5 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.5a is H or C.sub.1-3 alkyl; R.sup.6 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.8 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.9 is H, halogen or methyl; Y is CR.sup.a or N; m is 0, 1, 2 or 3; n is 0 or 1; or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. 8. The compound according to claim 1 of the formula ##STR00440## wherein X is O; R.sup.1 and R.sup.2 are independently ##STR00441## with the proviso that one of R.sup.1 and R.sup.2 must be ##STR00442## Z.sub.1 is N or CR.sup.a; Z.sub.2 is NR.sup.b; R.sup.a is H, halogen, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.b is H, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, --C(O)R.sup.a1, --C(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.a1 is H, C.sub.1-3 alkyl or C.sub.3-6 cycloalkyl; R.sup.3 is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; R.sup.3a is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; or R.sup.3 and R.sup.3a may be taken together to form a 3-4 membered carbocycle; or R.sup.3 and R.sup.3a may be taken together to form a C.dbd.CH.sub.2 substituent; R.sup.5 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.5a is H or C.sub.1-3 alkyl; R.sup.6 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.8 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.9 is H, halogen or methyl; Y is CR.sup.a or N; m is 0, 1, 2 or 3; n is 0 or 1; or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. 9. The compound according to claim 1 of the formula ##STR00443## wherein R.sup.1 and R.sup.2 are independently ##STR00444## with the proviso that one of R.sup.1 and R.sup.2 must be ##STR00445## Z.sub.1 is N or CR.sup.a; Z.sub.2 is NR.sup.b; R.sup.a is H, halogen, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.b is H, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, --C(O)R.sup.a1, --C(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.a1 is H, C.sub.1-3 alkyl or C.sub.3-6 cycloalkyl; R.sup.3 is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; R.sup.3a is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; or R.sup.3 and R.sup.3a may be taken together to form a 3-4 membered carbocycle; or R.sup.3 and R.sup.3a may be taken together to form a C.dbd.CH.sub.2 substituent; R.sup.5 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.5a is H or C.sub.1-3 alkyl; R.sup.6 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.8 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.9 is H, halogen or methyl; Y is CR.sup.a or N; m is 0, 1, 2 or 3; n is 0 or 1; or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. 10. The compound according to claim 1 of the formula ##STR00446## wherein R.sup.1 and R.sup.2 are independently ##STR00447## with the proviso that one of R.sup.1 and R.sup.2 must be ##STR00448## Z.sub.1 is N or CR.sup.a; Z.sub.2 is NR.sup.b; R.sup.a is H, halogen, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.b is H, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, --C(O)R.sup.a1, --C(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.a1 is H, C.sub.1-3 alkyl or C.sub.3-6 cycloalkyl; R.sup.3 is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; R.sup.3a is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; or R.sup.3 and R.sup.3a may be taken together to form a 3-4 membered carbocycle; or R.sup.3 and R.sup.3a may be taken together to form a C.dbd.CH.sub.2 substituent; R.sup.5 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.5a is H or C.sub.1-3 alkyl; R.sup.6 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.8 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.9 is H, halogen or methyl; Y is CR.sup.a or N; m is 0, 1, 2 or 3; n is 0 or 1; or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. 11. The compound according to claim 1 of the formula ##STR00449## wherein X is independently O or S; R.sup.1 and R.sup.2 are independently ##STR00450## with the proviso that one of R.sup.1 and R.sup.2 must be ##STR00451## Z.sub.1 is N or CR.sup.a; Z.sub.2 is NR.sup.b; R.sup.a is H, halogen, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.b is H, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, --C(O)R.sup.a1, --C(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.a1 is H, C.sub.1-3 alkyl or C.sub.3-6 cycloalkyl; R.sup.3 is F; R.sup.5 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.5a is H or C.sub.1-3 alkyl; R.sup.6 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.8 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.9 is H, halogen or methyl; Y is CR.sup.a or N; m is 0, 1, 2 or 3; n is 0 or 1; or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. 12. The compound according to claim 1 of the formula ##STR00452## wherein X is independently O or S; X.sup.1, X.sup.2, X.sup.3 and X.sup.4 are each independently O or NH; R.sup.1 and R.sup.2 are independently ##STR00453## with the proviso that one of R.sup.1 and R.sup.2 must be ##STR00454## Z.sub.1 is N or CR.sup.a; Z.sub.2 is NR.sup.b; R.sup.a is H, halogen, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.b is H, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, --C(O)R.sup.a1, --C(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.a1 is H, C.sub.1-3 alkyl or C.sub.3-6 cycloalkyl; R.sup.3 is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; R.sup.3a is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; or R.sup.3 and R.sup.3a may be taken together to form a 3-4 membered carbocycle; or R.sup.3 and R.sup.3a may be taken together to form a C.dbd.CH.sub.2 substituent; R.sup.5 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.5a is H or C.sub.1-3 alkyl; R.sup.6 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.8 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.9 is H, halogen or methyl; Y is CR.sup.a or N; m is 0, 1, 2 or 3; or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. 13. The compound according to claim 1 of the formula ##STR00455## wherein X is S; X.sup.1, X.sup.2, X.sup.3 and X.sup.4 are each independently O or NH; R.sup.1 and R.sup.2 are independently ##STR00456## with the proviso that one of R.sup.1 and R.sup.2 must be ##STR00457## Z.sub.1 is N or CR.sup.a; Z.sub.2 is NR.sup.b; R.sup.a is H, halogen, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.b is H, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, --C(O)R.sup.a1, --C(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.a1 is H, C.sub.1-3 alkyl or C.sub.3-6 cycloalkyl; R.sup.3 is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; R.sup.3a is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; or R.sup.3 and R.sup.3a may be taken together to form a 3-4 membered carbocycle; or R.sup.3 and R.sup.3a may be taken together to form a C.dbd.CH.sub.2 substituent; R.sup.5 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.5a is H or C.sub.1-3 alkyl; R.sup.6 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.8 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.9 is H, halogen or methyl; Y is CR.sup.a or N; m is 0, 1, 2 or 3; or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. 14. The compound according to claim 1 of the formula ##STR00458## wherein X is O; X.sup.1, X.sup.2, X.sup.3 and X.sup.4 are each independently O or NH; R.sup.1 and R.sup.2 are independently ##STR00459## with the proviso that one of R.sup.1 and R.sup.2 must be ##STR00460## Z.sub.1 is N or CR.sup.a; Z.sub.2 is NR.sup.b; R.sup.a is H, halogen, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.b is H, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, --C(O)R.sup.a1, --C(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.a1 is H, C.sub.1-3 alkyl or C.sub.3-6 cycloalkyl; R.sup.3 is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; R.sup.3a is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; or R.sup.3 and R.sup.3a may be taken together to form a 3-4 membered carbocycle; or R.sup.3 and R.sup.3a may be taken together to form a C.dbd.CH.sub.2 substituent; R.sup.5 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.5a is H or C.sub.1-3 alkyl; R.sup.6 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.8 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.9 is H, halogen or methyl; Y is CR.sup.a or N; m is 0, 1, 2 or 3; or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. 15. The compound according to claim 1 of the formula ##STR00461## wherein X.sup.1, X.sup.2, X.sup.3 and X.sup.4 are each independently O or NH; R.sup.1 and R.sup.2 are each independently ##STR00462## with the proviso that one of R.sup.1 and R.sup.2 must be ##STR00463## Z.sub.1 is N or CR.sup.a; Z.sub.2 is NR.sup.b; R.sup.a is H, halogen, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.b is H, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, --C(O)R.sup.a1, --C(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.a1 is H, C.sub.1-3 alkyl or C.sub.3-6 cycloalkyl; R.sup.3 is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; R.sup.3a is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; or R.sup.3 and R.sup.3a may be taken together to form a 3-4 membered carbocycle; or R.sup.3 and R.sup.3a may be taken together to form a C.dbd.CH.sub.2 substituent; R.sup.5 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.5a is H or C.sub.1-3 alkyl; R.sup.6 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.8 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.9 is H, halogen or methyl; Y is CR.sup.a or N; m is 0, 1, 2 or 3; or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. 16. The compound according to claim 1 of the formula ##STR00464## wherein X.sup.1, X.sup.2, X.sup.3 and X.sup.4 are each independently O or NH; R.sup.1 and R.sup.2 are each independently ##STR00465## with the proviso that one of R.sup.1 and R.sup.2 must be ##STR00466## Z.sub.1 is N or CR.sup.a; Z.sub.2 is NR.sup.b; R.sup.a is H, halogen, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.b is H, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, --C(O)R.sup.a1, --C(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.a1 is H, C.sub.1-3 alkyl or C.sub.3-6 cycloalkyl; R.sup.3 is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; R.sup.3a is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; or R.sup.3 and R.sup.3a may be taken together to form a 3-4 membered carbocycle; or R.sup.3 and R.sup.3a may be taken together to form a C.dbd.CH.sub.2 substituent; R.sup.5 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.5a is H or C.sub.1-3 alkyl; R.sup.6 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.8 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.9 is H, halogen or methyl; Y is CR.sup.a or N; m is 0, 1, 2 or 3; or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. 17. The compound according to claim 1 of the formula ##STR00467## wherein X is independently O or S; R.sup.1 and R.sup.2 are each independently ##STR00468## with the proviso that one of R.sup.1 and R.sup.2 must be ##STR00469## Z.sub.1 is N or CR.sup.a; Z.sub.2 is NR.sup.b; R.sup.a is H, halogen, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.b is H, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, --C(O)R.sup.a1, --C(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.a1 is H, C.sub.1-3 alkyl or C.sub.3-6 cycloalkyl; R.sup.3 is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; R.sup.3a is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; or R.sup.3 and R.sup.3a may be taken together to form a 3-4 membered carbocycle; or R.sup.3 and R.sup.3a may be taken together to form a C.dbd.CH.sub.2 substituent; R.sup.5 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.5a is H or C.sub.1-3 alkyl; R.sup.6 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.8 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.9 is H, halogen or methyl; Y is CR.sup.a or N; m is 0, 1, 2 or 3; or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. 18. The compound according to claim 1 of the formula ##STR00470## wherein X is S; R.sup.1 and R.sup.2 are each independently ##STR00471## with the proviso that one of R.sup.1 and R.sup.2 must be ##STR00472## Z.sub.1 is N or CR.sup.a; Z.sub.2 is NR.sup.b; R.sup.a is H, halogen, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.b is H, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, --C(O)R.sup.a1, --C(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.a1 is H, C.sub.1-3 alkyl or C.sub.3-6 cycloalkyl; R.sup.3 is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; R.sup.3a is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; or R.sup.3 and R.sup.3a may be taken together to form a 3-4 membered carbocycle; or R.sup.3 and R.sup.3a may be taken together to form a C.dbd.CH.sub.2 substituent; R.sup.5 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.5a is H or C.sub.1-3 alkyl; R.sup.6 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.8 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.9 is H, halogen or methyl; Y is CR.sup.a or N; m is 0, 1, 2 or 3; or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. 19. The compound according to claim 1 of the formula ##STR00473## wherein X is O; R.sup.1 and R.sup.2 are each independently ##STR00474## with the proviso that one of R.sup.1 and R.sup.2 must be ##STR00475## Z.sub.1 is N or CR.sup.a; Z.sub.2 is NR.sup.b; R.sup.a is H, halogen, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.b is H, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, --C(O)R.sup.a1, --C(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.a1 is H, C.sub.1-3 alkyl or C.sub.3-6 cycloalkyl; R.sup.3 is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; R.sup.3a is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; or R.sup.3 and R.sup.3a may be taken together to form a 3-4 membered carbocycle; or R.sup.3 and R.sup.3a may be taken together to form a C.dbd.CH.sub.2 substituent; R.sup.5 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.5a is H or C.sub.1-3 alkyl; R.sup.6 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.8 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.9 is H, halogen or methyl; Y is CR.sup.a or N; m is 0, 1, 2 or 3; or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. 20. The compound according to claim 1 of the formula ##STR00476## wherein R.sup.1 and R.sup.2 are each independently ##STR00477## with the proviso that one of R.sup.1 and R.sup.2 must be ##STR00478## Z.sub.1 is N or CR.sup.a; Z.sub.2 is NR.sup.b; R.sup.a is H, halogen, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.b is H, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, --C(O)R.sup.a1, --C(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.a1 is H, C.sub.1-3 alkyl or C.sub.3-6 cycloalkyl; R.sup.3 is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; R.sup.3a is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; or R.sup.3 and R.sup.3a may be taken together to form a 3-4 membered carbocycle; or R.sup.3 and R.sup.3a may be taken together to form a C.dbd.CH.sub.2 substituent; R.sup.5 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.5a is H or C.sub.1-3 alkyl; R.sup.6 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.8 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.9 is H, halogen or methyl; Y is CR.sup.a or N; m is 0, 1, 2 or 3; or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. 21. The compound according to claim 1 of the formula ##STR00479## wherein R.sup.1 and R.sup.2 are each independently ##STR00480## with the proviso that one of R.sup.1 and R.sup.2 must be ##STR00481## Z.sub.1 is N or CR.sup.a; Z.sub.2 is NR.sup.b; R.sup.a is H, halogen, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.b is H, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, --C(O)R.sup.a1, --C(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.a1 is H, C.sub.1-3 alkyl or C.sub.3-6 cycloalkyl; R.sup.3 is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; R.sup.3a is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; or R.sup.3 and R.sup.3a may be taken together to form a 3-4 membered carbocycle; or R.sup.3 and R.sup.3a may be taken together to form a C.dbd.CH.sub.2 substituent; R.sup.5 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.5a is H or C.sub.1-3 alkyl; R.sup.6 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.8 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.9 is H, halogen or methyl; Y is CR.sup.a or N; m is 0, 1, 2 or 3; or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. 22. The compound according to claim 1 of the formula ##STR00482## ##STR00483## ##STR00484## or a tautomer or stereoisomer thereof. 23. A pharmaceutically acceptable salt of a compound according to claim 1 of the formula ##STR00485## ##STR00486## ##STR00487## 24. A compound of formula II ##STR00488## wherein X is independently O or S; X.sup.1, X.sup.2, X.sup.3 and X.sup.4 are each independently O or NH; R.sup.1 and R.sup.2 are each independently ##STR00489## with the proviso that one of R.sup.1 and R.sup.2 must be ##STR00490## Z.sub.1 is N or CR.sup.a; Z.sub.2 is NR.sup.b; R.sup.a is H, halogen, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.b is H, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, --C(O)R.sup.a1, --C(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.a1 is H, C.sub.1-3 alkyl or C.sub.3-6 cycloalkyl; R.sup.4 is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; R.sup.4a is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; or R.sup.4 and R.sup.4a may be taken together to form a 3-4 membered carbocycle; or R.sup.4 and R.sup.4a may be taken together to form a C.dbd.CH.sub.2 substituent; R.sup.5 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; or two R.sup.5 groups may be taken together to form a 5-6 membered carbocyclic or heterocyclic group; or R.sup.5 and R.sup.6 may be taken together to form a 5-6 membered carbocyclic or heterocyclic group; R.sup.5a is H or C.sub.1-3 alkyl; R.sup.6 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.8 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.9 is H, halogen or methyl; Y is CR.sup.a or N; m is 0, 1, 2 or 3; n is 0 or 1; or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. 25. The compound according to claim 24 of formula II ##STR00491## wherein X is S; X.sup.1, X.sup.2, X.sup.3 and X.sup.4 are each independently O or NH; R.sup.1 and R.sup.2 are each independently ##STR00492## with the proviso that one of R.sup.1 and R.sup.2 must be ##STR00493## Z.sub.1 is N or CR.sup.a; Z.sub.2 is NR.sup.b; R.sup.a is H, halogen, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.b is H, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, --C(O)R.sup.a1, --C(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.a1 is H, C.sub.1-3 alkyl or C.sub.3-6 cycloalkyl; R.sup.4 is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; R.sup.4a is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; or R.sup.4 and R.sup.4a may be taken together to form a 3-4 membered carbocycle; or R.sup.4 and R.sup.4a may be taken together to form a C.dbd.CH.sub.2 substituent; R.sup.5 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.5a is H or C.sub.1-3 alkyl; R.sup.6 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.8 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.9 is H, halogen or methyl; Y is CR.sup.a or N; m is 0, 1, 2 or 3; n is 0 or 1; or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. 26. The compound according to claim 24 of formula II ##STR00494## wherein X is O; X.sup.1, X.sup.2, X.sup.3 and X.sup.4 are each independently O or NH; R.sup.1 and R.sup.2 are each independently ##STR00495## with the proviso that one of R.sup.1 and R.sup.2 must be ##STR00496## Z.sub.1 is N or CR.sup.a; Z.sub.2 is NR.sup.b; R.sup.a is H, halogen, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.b is H, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, --C(O)R.sup.a1, --C(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.a1 is H, C.sub.1-3 alkyl or C.sub.3-6 cycloalkyl; R.sup.4 is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; R.sup.4a is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; or R.sup.4 and R.sup.4a may be taken together to form a 3-4 membered carbocycle; or R.sup.4 and R.sup.4a may be taken together to form a C.dbd.CH.sub.2 substituent; R.sup.5 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.5a is H or C.sub.1-3 alkyl; R.sup.6 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.8 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.9 is H, halogen or methyl; Y is CR.sup.a or N; m is 0, 1, 2 or 3; n is 0 or 1; or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. 27. The compound according to claim 24 of the formula ##STR00497## wherein X.sup.1, X.sup.2, X.sup.3 and X.sup.4 are each independently O or NH; R.sup.1 and R.sup.2 are each independently ##STR00498## with the proviso that one of R.sup.1 and R.sup.2 must be ##STR00499## Z.sub.1 is N or CR.sup.a; Z.sub.2 is NR.sup.b; R.sup.a is H, halogen, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.b is H, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, --C(O)R.sup.a1, --C(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.a1 is H, C.sub.1-3 alkyl or C.sub.3-6 cycloalkyl; R.sup.4 is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; R.sup.4a is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; or R.sup.4 and R.sup.4a may be taken together to form a 3-4 membered carbocycle; or R.sup.4 and R.sup.4a may be taken together to form a C.dbd.CH.sub.2 substituent; R.sup.5 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.5a is H or C.sub.1-3 alkyl; R.sup.6 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.8 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.9 is H, halogen or methyl; Y is CR.sup.a or N; m is 0, 1, 2 or 3; n is 0 or 1; or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. 28. The compound according to claim 24 of the formula ##STR00500## wherein X.sup.1, X.sup.2, X.sup.3 and X.sup.4 are each independently O or NH; R.sup.1 and R.sup.2 are each independently ##STR00501## with the proviso that one of R.sup.1 and R.sup.2 must be ##STR00502## Z.sub.1 is N or CR.sup.a; Z.sub.2 is NR.sup.b; R.sup.a is H, halogen, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.b is H, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, --C(O)R.sup.a1, --C(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.a1 is H, C.sub.1-3 alkyl or C.sub.3-6 cycloalkyl; R.sup.4 is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; R.sup.4a is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; or R.sup.4 and R.sup.4a may be taken together to form a 3-4 membered carbocycle; or R.sup.4 and R.sup.4a may be taken together to form a C.dbd.CH.sub.2 substituent; R.sup.5 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.5a is H or C.sub.1-3 alkyl; R.sup.6 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.8 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.9 is H, halogen or methyl; Y is CR.sup.a or N; m is 0, 1, 2 or 3; n is 0 or 1; or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. 29. The compound according to claim 24 of the formula ##STR00503## wherein X is independently O or S; R.sup.1 and R.sup.2 are each independently ##STR00504## with the proviso that one of R.sup.1 and R.sup.2 must be ##STR00505## Z.sub.1 is N or CR.sup.a; Z.sub.2 is NR.sup.b; R.sup.a is H, halogen, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.b is H, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, --C(O)R.sup.a1, --C(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.a1 is H, C.sub.1-3 alkyl or C.sub.3-6 cycloalkyl; R.sup.4 is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; R.sup.4a is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; or R.sup.4 and R.sup.4a may be taken together to form a 3-4 membered carbocycle; or R.sup.4 and R.sup.4a may be taken together to form a C.dbd.CH.sub.2 substituent; R.sup.5 is H, halogen, Cl-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.5a is H or C.sub.1-3 alkyl; R.sup.6 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.8 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.9 is H, halogen or methyl; Y is CR.sup.a or N; m is 0, 1, 2 or 3; n is 0 or 1; or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. 30. The compound according to claim 24 of the formula ##STR00506## wherein X is S; R.sup.1 and R.sup.2 are each independently ##STR00507## with the proviso that one of R.sup.1 and R.sup.2 must be ##STR00508## Z.sub.1 is N or CR.sup.a; Z.sub.2 is NR.sup.b; R.sup.a is H, halogen, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.b is H, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, --C(O)R.sup.a1, --C(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.a1 is H, C.sub.1-3 alkyl or C.sub.3-6 cycloalkyl; R.sup.4 is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; R.sup.4a is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; or R.sup.4 and R.sup.4a may be taken together to form a 3-4 membered carbocycle; or R.sup.4 and R.sup.4a may be taken together to form a C.dbd.CH.sub.2 substituent; R.sup.5 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.5a is H or C.sub.1-3 alkyl; R.sup.6 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.8 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.9 is H, halogen or methyl; Y is CR.sup.a or N; m is 0, 1, 2 or 3; n is 0 or 1; or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. 31. The compound according to claim 24 of the formula ##STR00509## wherein X is O; R.sup.1 and R.sup.2 are each independently ##STR00510## with the proviso that one of R.sup.1 and R.sup.2 must be ##STR00511## Z.sub.1 is N or CR.sup.a; Z.sub.2 is NR.sup.b; R.sup.a is H, halogen, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.b is H, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, --C(O)R.sup.a1, --C(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.a1 is H, C.sub.1-3 alkyl or C.sub.3-6 cycloalkyl; R.sup.4 is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; R.sup.4a is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; or R.sup.4 and R.sup.4a may be taken together to form a 3-4 membered carbocycle; or R.sup.4 and R.sup.4a may be taken together to form a C.dbd.CH.sub.2 substituent; R.sup.5 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.5a is H or C.sub.1-3 alkyl; R.sup.6 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.8 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.9 is H, halogen or methyl; Y is CR.sup.a or N; m is 0, 1, 2 or 3; n is 0 or 1; or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. 32. The compound according to claim 24 of the formula ##STR00512## wherein X is independently O or S; X.sup.1, X.sup.2, X.sup.3 and X.sup.4 are each independently O or NH; R.sup.1 and R.sup.2 are each independently ##STR00513## with the proviso that one of R.sup.1 and R.sup.2 must be ##STR00514## Z.sub.1 is N or CR.sup.a; Z.sub.2 is NR.sup.b; R.sup.a is H, halogen, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.b is H, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, --C(O)R.sup.a1, --C(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.a1 is H, C.sub.1-3 alkyl or C.sub.3-6 cycloalkyl; R.sup.4 is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; R.sup.4a is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; or R.sup.4 and R.sup.4a may be taken together to form a 3-4 membered carbocycle; or R.sup.4 and R.sup.4a may be taken together to form a C.dbd.CH.sub.2 substituent; R.sup.5 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.5a is H or C.sub.1-3 alkyl; R.sup.6 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.8 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.9 is H, halogen or methyl; Y is CR.sup.a or N; m is 0, 1, 2 or 3; or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. 33. The compound according to claim 24 of the formula ##STR00515## wherein X is S; X.sup.1, X.sup.2, X.sup.3 and X.sup.4 are each independently O or NH; R.sup.1 and R.sup.2 are each independently ##STR00516## with the proviso that one of R.sup.1 and R.sup.2 must be ##STR00517## Z.sub.1 is N or CR.sup.a; Z.sub.2 is NR.sup.b; R.sup.a is H, halogen, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.b is H, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, --C(O)R.sup.a1, --C(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.a1 is H, C.sub.1-3 alkyl or C.sub.3-6 cycloalkyl; R.sup.4 is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; R.sup.4a is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; or R.sup.4 and R.sup.4a may be taken together to form a 3-4 membered carbocycle; or R.sup.4 and R.sup.4a may be taken together to form a C.dbd.CH.sub.2 substituent; R.sup.5 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.5a is H or C.sub.1-3 alkyl; R.sup.6 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.8 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.9 is H, halogen or methyl; Y is CR.sup.a or N; m is 0, 1, 2 or 3; or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. 34. The compound according to claim 24 of the formula ##STR00518## wherein X is O; X.sup.1, X.sup.2, X.sup.3 and X.sup.4 are each independently O or NH; R.sup.1 and R.sup.2 are each independently ##STR00519## with the proviso that one of R.sup.1 and R.sup.2 must be ##STR00520## Z.sub.1 is N or CR.sup.a; Z.sub.2 is NR.sup.b; R.sup.a is H, halogen, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.b is H, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, --C(O)R.sup.a1, --C(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.a1 is H, C.sub.1-3 alkyl or C.sub.3-6 cycloalkyl; R.sup.4 is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; R.sup.4a is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; or R.sup.4 and R.sup.4a may be taken together to form a 3-4 membered carbocycle; or R.sup.4 and R.sup.4a may be taken together to form a C.dbd.CH.sub.2 substituent; R.sup.5 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.5a is H or C.sub.1-3 alkyl; R.sup.6 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.8 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.9 is H, halogen or methyl; Y is CR.sup.a or N; m is 0, 1, 2 or 3; or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. 35. The compound according to claim 24 of the formula ##STR00521## wherein X.sup.1, X.sup.2, X.sup.3 and X.sup.4 are each independently O or NH; R.sup.1 and R.sup.2 are each independently ##STR00522## with the proviso that one of R.sup.1 and R.sup.2 must be ##STR00523## Z.sub.1 is N or CR.sup.a; Z.sub.2 is NR.sup.b; R.sup.a is H, halogen, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.b is H, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, --C(O)R.sup.a1, --C(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.a1 is H, C.sub.1-3 alkyl or C.sub.3-6 cycloalkyl; R.sup.4 is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; R.sup.4a is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; or R.sup.4 and R.sup.4a may be taken together to form a 3-4 membered carbocycle; or R.sup.4 and R.sup.4a may be taken together to form a C.dbd.CH.sub.2 substituent; R.sup.5 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.5a is H or C.sub.1-3 alkyl; R.sup.6 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.8 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.9 is H, halogen or methyl; Y is CR.sup.a or N; m is 0, 1, 2 or 3; or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. 36. The compound according to claim 24 of the formula ##STR00524## wherein X.sup.1, X.sup.2, X.sup.3 and X.sup.4 are each independently O or NH; R.sup.1 and R.sup.2 are each independently ##STR00525## with the proviso that one of R.sup.1 and R.sup.2 must be ##STR00526## Z.sub.1 is N or CR.sup.a; Z.sub.2 is NR.sup.b; R.sup.a is H, halogen, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.b is H, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, --C(O)R.sup.a1, --C(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.a1 is H, C.sub.1-3 alkyl or C.sub.3-6 cycloalkyl; R.sup.4 is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; R.sup.4a is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; or R.sup.4 and R.sup.4a may be taken together to form a 3-4 membered carbocycle; or R.sup.4 and R.sup.4a may be taken together to form a C.dbd.CH.sub.2 substituent; R.sup.5 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.5a is H or C.sub.1-3 alkyl; R.sup.6 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.8 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.9 is H, halogen or methyl; Y is CR.sup.a or N; m is 0, 1, 2 or 3; or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. 37. The compound according to claim 24 of the formula ##STR00527## wherein X is independently O or S; R.sup.1 and R.sup.2 are each independently ##STR00528## with the proviso that one of R.sup.1 and R.sup.2 must be ##STR00529## Z.sub.1 is N or CR.sup.a; Z.sub.2 is NR.sup.b; R.sup.a is H, halogen, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.b is H, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, --C(O)R.sup.a1, --C(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.a1 is H, C.sub.1-3 alkyl or C.sub.3-6 cycloalkyl; R.sup.4 is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; R.sup.4a is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; or R.sup.4 and R.sup.4a may be taken together to form a 3-4 membered carbocycle; or R.sup.4 and R.sup.4a may be taken together to form a C.dbd.CH.sub.2 substituent; R.sup.5 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.5a is H or C.sub.1-3 alkyl; R.sup.6 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.8 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.9 is H, halogen or methyl; Y is CR.sup.a or N; m is 0, 1, 2 or 3; or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. 38. The compound according to claim 24 of the formula ##STR00530## wherein X is S; R.sup.1 and R.sup.2 are each independently ##STR00531## with the proviso that one of R.sup.1 and R.sup.2 must be ##STR00532## Z.sub.1 is N or CR.sup.a; Z.sub.2 is NR.sup.b; R.sup.a is H, halogen, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.b is H, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, --C(O)R.sup.a1, --C(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.a1 is H, C.sub.1-3 alkyl or C.sub.3-6 cycloalkyl; R.sup.4 is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; R.sup.4a is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; or R.sup.4 and R.sup.4a may be taken together to form a 3-4 membered carbocycle; or R.sup.4 and R.sup.4a may be taken together to form a C.dbd.CH.sub.2 substituent; R.sup.5 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.5a is H or C.sub.1-3 alkyl; R.sup.6 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.8 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.9 is H, halogen or methyl; Y is CR.sup.a or N; m is 0, 1, 2 or 3; or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. 39. The compound according to claim 24 of the formula ##STR00533## wherein X is O; R.sup.1 and R.sup.2 are each independently ##STR00534## with the proviso that one of R.sup.1 and R.sup.2 must be ##STR00535## Z.sub.1 is N or CR.sup.a; Z.sub.2 is NR.sup.b; R.sup.a is H, halogen, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.b is H, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, --C(O)R.sup.a1, --C(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.a1 is H, C.sub.1-3 alkyl or C.sub.3-6 cycloalkyl; R.sup.4 is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; R.sup.4a is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; or R.sup.4 and R.sup.4a may be taken together to form a 3-4 membered carbocycle; or R.sup.4 and R.sup.4a may be taken together to form a C.dbd.CH.sub.2 substituent; R.sup.5 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.5a is H or C.sub.1-3 alkyl; R.sup.6 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.8 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.9 is H, halogen or methyl; Y is CR.sup.a or N; m is 0, 1, 2 or 3; or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. 40. The compound according to claim 24 of the formula ##STR00536## wherein R.sup.1 and R.sup.2 are each independently ##STR00537## with the proviso that one of R.sup.1 and R.sup.2 must be ##STR00538## Z.sub.1 is N or CR.sup.a; Z.sub.2 is NR.sup.b; R.sup.a is H, halogen, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.b is H, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, --C(O)R.sup.a1, --C(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.a1 is H, C.sub.1-3 alkyl or C.sub.3-6 cycloalkyl; R.sup.4 is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; R.sup.4a is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; or R.sup.4 and R.sup.4a may be taken together to form a 3-4 membered carbocycle; or R.sup.4 and R.sup.4a may be taken together to form a C.dbd.CH.sub.2 substituent; R.sup.5 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.5a is H or C.sub.1-3 alkyl; R.sup.6 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.8 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.9 is H, halogen or methyl; Y is CR.sup.a or N; m is 0, 1, 2 or 3; or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. 41. The compound according to claim 24 of the formula ##STR00539## wherein R.sup.1 and R.sup.2 are each independently ##STR00540## with the proviso that one of R.sup.1 and R.sup.2 must be ##STR00541## Z.sub.1 is N or CR.sup.a; Z.sub.2 is NR.sup.b; R.sup.a is H, halogen, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.b is H, C.sub.1-6 alkyl substituted with 0-6 R.sup.5, C.sub.3-6 cycloalkyl substituted with 0-6 R.sup.5, --C(O)R.sup.a1, --C(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.a1 is H, C.sub.1-3 alkyl or C.sub.3-6 cycloalkyl; R.sup.4 is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; R.sup.4a is H, CH.sub.3, halogen, --NR.sup.a1R.sup.a1 or OR.sup.a1; or R.sup.4 and R.sup.4a may be taken together to form a 3-4 membered carbocycle; or R.sup.4 and R.sup.4a may be taken together to form a C.dbd.CH.sub.2 substituent; R.sup.5 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.5a is H or C.sub.1-3 alkyl; R.sup.6 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.8 is H, halogen, C.sub.1-3 alkyl, CN, NO.sub.2, OH, OR.sup.a1, SR.sup.a1, --C(O)NR.sup.a1R.sup.a1, --COOR.sup.a1, --OC(O)R.sup.a1, --OC(O)NR.sup.a1R.sup.a1, --NR.sup.a1R.sup.a1, --NR.sup.a1C(O)R.sup.a1, --NR.sup.a1COOR.sup.a1, --NR.sup.a1C(O)NR.sup.a1R.sup.a1, --NR.sup.a1S(O).sub.2R.sup.a1, --NR.sup.a1S(O).sub.2NR.sup.a1R.sup.a1, --S(O)R.sup.a1, --S(O)NR.sup.a1R.sup.a1, --S(O).sub.2R.sup.a1 or S(O).sub.2NR.sup.a1R.sup.a1; R.sup.9 is H, halogen or methyl; Y is CR.sup.a or N; m is 0, 1, 2 or 3; or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. 42. The compound according to claim 24 of the formula ##STR00542## or a tautomer or stereoisomer thereof. 43. A pharmaceutically acceptable salt of a compound according to claim 24 of the formula ##STR00543## 44. A compound of the formula ##STR00544## ##STR00545## ##STR00546## or a tautomer or stereoisomer thereof. 45. A pharmaceutically acceptable salt of a compound of the formula ##STR00547## ##STR00548## ##STR00549## 46. A compound of the formula ##STR00550## ##STR00551## ##STR00552## ##STR00553## or a tautomer or stereoisomer thereof. 47. A pharmaceutically acceptable salt of a compound of the formula ##STR00554## ##STR00555## ##STR00556## ##STR00557## 48. The compound which is (1R,6S,8R,9R,15R,17R,18R)-17-(6-amino-9H-purin-9-yl)-18-fluoro-8-{9-hydro- xy-3H-imidazo[1,2-a]purin-3-yl}-3,12-disulfanyl-2,4,11,13,16-pentaoxa-3.la- mda..sup.5,12.lamda..sup.5-diphosphatricyclo[13.3.0.0.sup.6,9]octadecane-3- ,12-dione, (1R,6S,8R,9R,15R,17R,18R)-8-(6-amino-9H-purin-9-yl)-8-hydroxy-1- 7-{9-oxo-3H,4H,9H-imidazo[1,2-a]purin-3-yl}-3,12-disulfanyl-2,4,11,13,16-p- entaoxa-3.lamda..sup.5,12.lamda..sup.5-diphosphatricyclo[13.2.1.0.sup.6,9]- octadecane-3,12-dione, (1R,6S,8R,9R,15R,17R,18R)-17-(6-amino-9H-purin-9-yl)-18-fluoro-8-{3H-imid- azo[2,1-f]purin-3-yl}-3,12-disulfanyl-2,4,11,13,16-pentaoxa-3.lamda..sup.5- ,12.lamda..sup.5-diphosphatricyclo[13.3.0.0.sup.6,9]octadecane-3,12dione, (1R,6S,8R,9R,15R,17R,18R)-8-(6-amino-9H-purin-9-yl)-3,18-dihydroxy-17-{9-- oxo-3H,4H,9H-imidazo[1,2-a]purin-3-yl}-12-sulfanyl-2,4,11,13,16-pentaoxa-3- .lamda..sup.5,12.lamda..sup.5-diphosphatricyclo[13.2.1.0.sup.6,9]octadecan- e-3,12-dione, (1S,6S,8R,9R,15R,17R,18R)-8-(6-amino-9H-purin-9-yl)-18-hydroxy-17-{9-oxo-- 3H,5H,9H-imidazo[1,2-a]purin-3-yl}-3,12-disulfanyl-2,4,11,13,16-pentaoxa-3- .lamda..sup.5,12.lamda..sup.5-diphosphatricyclo[13.3.0.0.sup.6,9]octadecan- e-3,12-dione, (1S,6S,8R,9R,15R,17R,18R)-8-(6-amino-9H-purin-9-yl)-18-fluoro-17-{9-oxo-3- H,4H,9H-imidazo[1,2-a]purin-3-yl}-3,12-disulfanyl-2,4,11,13,16-pentaoxa-3.- lamda..sup.5,12.lamda..sup.5-diphosphatricyclo[13.2.1.0.sup.6,9]octadecane- -3,12-dione, (1S,6S,8R,9R,15R,17R,18R)-8-(6-amino-9H-purin-9-yl)-18-fluoro-17-{3H-imid- azo[2,1-f]purin-3-yl}-3,12-disulfanyl-2,4,11,13,16-pentaoxa-3.lamda..sup.5- ,12.lamda..sup.5-diphosphatricyclo[13.2.1.0.sup.6,9]octadecane-3,12-dione, (1S,6S,8R,9R,15R,17R,18R)-8-(6-amino-9H-purin-9-yl)-18-fluoro-17-{3H-imid- azo[2,1-f]purin-3-yl}-3,12-disulfanyl-2,4,11,13,16-pentaoxa-3.lamda..sup.5- ,12.lamda..sup.5-diphosphatricyclo[13.2.1.0.sup.6,9]octadecane-3,12-dione, 4-[(1R,6S,8R,9S,15R,17R,18R)-17-(6-amino-9H-purin-9-yl)-18-fluoro-3,12-di- oxo-3,12-disulfanyl-2,4,11,13,16-pentaoxa-3.lamda..sup.5,12.lamda..sup.5-d- iphosphatricyclo[13.3.0.0.sup.6,9]octadecan-8-yl]pyridine-2-carboxamide, 4-[(1R,6S,8R,9S,15R,17R,18S)-17-(6-amino-9H-purin-9-yl)-18-fluoro-3,12-di- oxo-3,12-disulfanyl-2,4,11,13,16-pentaoxa-3.lamda..sup.5,12.lamda..sup.5-d- iphosphatricyclo[13.3.0.0.sup.6,9]octadecan-8-yl]pyridine-2-carboxamide, 4-[(1R,6S,8R,9S,15R,17R,18R)-17-(6-amino-9H-purin-9-yl)-18-fluoro-3,12-di- hydroxy-3,12-dioxo-2,4,11,13,16-pentaoxa-3.lamda..sup.5,12.lamda..sup.5-di- phosphatricyclo[13.3.0.0.sup.6,9]octadecan-8-yl]pyridine-2-carboxamide, 4-[(1R,6S,8R,9S,15R,17R,18R)-17-(6-amino-9H-purin-9-yl)-18-fluoro-12-hydr- oxy-3,12-dioxo-3-sulfanyl-2,4,11,13,16-pentaoxa-3.lamda..sup.5,12.lamda..s- up.5-diphosphatricyclo[13.3.0.0.sup.6,9]octadecan-8-yl]pyridine-2-carboxam- ide, 4-[(1S,7S,8R,10S,16R,17R)-17-(6-amino-9H-purin-9-yl)-4,13-dioxo-4,13-- disulfanyl-3,5,12,14-tetraoxa-4.lamda..sup.5,13.lamda..sup.5-diphosphatric- yclo[14.2.0.0.sup.7,10]octadecan-8-yl]pyridine-2-carboxamide, (1R,6S,8R,9R,15R,17R,18R)-8-(6-amino-9H-purin-9-yl)-18-fluoro-3,12-dihydr- oxy-17-{3H-imidazo[2,1-f]purin-3-yl}-2,4,11,13,16-pentaoxa-3.lamda..sup.5,- 12.lamda..sup.5-diphosphatricyclo[13.3.0.0.sup.6,9]octadecane-3,12-dione, (1R,6S,8R,9R,15R,17R,18R)-8-(6-amino-9H-purin-9-yl)-18-fluoro-17-{3H-imid- azo[2,1-f]purin-3-yl}-3,12-disulfanyl-2,4,11,13,16-pentaoxa-3.lamda..sup.5- ,12.lamda..sup.5-diphosphatricyclo[13.3.0.0.sup.6,9]octadecane-3,12-dione, (1R,6S,8R,9R,15R,17R,18R)-8-(6-chloro-9H-purin-9-yl)-18-fluoro-17-{3H-imi- dazo[2,1-f]purin-3-yl}-3,12-disulfanyl-2,4,11,13,16-pentaoxa-3.lamda..sup.- 5,12.lamda..sup.5-diphosphatricyclo[13.3.0.0.sup.6,9]octadecane-3,12-dione- , 4-[(1R,6S,8R,9S,15R,17R,18R)-18-fluoro-17-{3H-imidazo[2,1-f]purin-3-yl}-- 3,12-dioxo-3,12-disulfanyl-2,4,11,13,16-pentaoxa-3.lamda..sup.5,12.lamda..- sup.5-diphosphatricyclo[13.3.0.0.sup.6,9]octadecan-8-yl]pyridine-2-carboxa- mide, 4-[(1R,6S,8R,9R,15R,17S,18R)-8-(6-amino-9H-purin-9-yl)-18-hydroxy-3,- 12-dioxo-3,12-disulfanyl-2,4,11,13,16-pentaoxa-3.lamda..sup.5,12.lamda..su- p.5-diphosphatricyclo[13.2.1.0.sup.6,9]octadecan-17-yl]pyridine-2-carboxam- ide, (1R,6S,8R,9R,15R,17R,18R)-17-(6-amino-9H-purin-9-yl)-18-fluoro-8-{5-o- xo-5H,8H,9H-[1,2,4]triazolo[4,3-a]purin-8-yl}-3,12-disulfanyl-2,4,11,13,16- -pentaoxa-3.lamda..sup.5,12.lamda..sup.5-diphosphatricyclo[13.3.0.0.sup.6,- 9]octadecane-3,12-dione, (1R,6S,8R,9R,15R,17R,18R)-17-(6-amino-9H-purin-9-yl)-18-fluoro-8-(6-oxo-6- ,9-dihydro-1H-purin-9-yl)-3,12-disulfanyl-2,4,11,13,16-pentaoxa-3.lamda..s- up.5,12.lamda..sup.5-diphosphatricyclo[13.3.0.0.sup.6,9]octadecane-3,12-di- one, (1R,6S,8R,9R,15R,17R,18R)-17-(6-amino-9H-purin-9-yl)-18-fluoro-8-{8-o- xo-4H,5H,8H-[1,2,3,4]tetrazolo[1,5-a]purin-5-yl}-3,12-disulfanyl-2,4,11,13- ,16-pentaoxa-3.lamda..sup.5,12.lamda..sup.5-diphosphatricyclo[13.3.0.0.sup- .6,9]octadecane-3,12-dione or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. 49. A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers, diluents or excipients. 50. A pharmaceutical composition comprising a compound according to claim 24 or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers, diluents or excipients. 51. A combination pharmaceutical product comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof together with one or more other therapeutically active agents. 52. A combination pharmaceutical product comprising a compound according to claim 24 or a pharmaceutically acceptable salt thereof together with one or more other therapeutically active agents. 53. A compound according to claim 1 or a pharmaceutically acceptable salt thereof for use in therapy. 54. A compound according to claim 24 or a pharmaceutically acceptable salt thereof for use in therapy. 55. A compound or a pharmaceutically acceptable salt thereof for use according to claim 1, wherein the disease or condition is cancer. 56. A compound or a pharmaceutically acceptable salt thereof for use according to claim 24, wherein the disease or condition is cancer. 57. A method of treating diseases and conditions in which the modulation of STING is indicated in a subject in need thereof, wherein the disease is cancer, which comprises administering a therapeutically effective amount of compound according to claim 1 or a pharmaceutically acceptable salt thereof. 58. A method of treating diseases and conditions in which the modulation of STING is indicated in a subject in need thereof, wherein the disease is cancer, which comprises administering a therapeutically effective amount of compound according to claim 24 or a pharmaceutically acceptable salt thereof. 59. A method of treating cancer comprising administering a therapeutically effective amount of one or more compounds according to claim 1 or a pharmaceutically acceptable salt thereof. 60. A method of treating cancer comprising administering a therapeutically effective amount of one or more compounds according to claim 24 or a pharmaceutically acceptable salt thereof. 61. The method of claim 59 wherein the cancer is small cell lung cancer, non-small cell lung cancer, colorectal cancer, melanoma, renal cell carcinoma, head and neck cancer, Hodgkin's lymphoma, bladder cancer, esophageal carcinoma, gastric carcinoma, ovarian carcinoma, cervical carcinoma, pancreatic carcinoma, prostate carcinoma, breast cancers, urinary carcinoma, brain tumors such as glioblastoma, non-Hodgkin's lymphoma, acute lymphatic leukemia (ALL), chronic lymphatic leukemia (CLL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), hepatocellular carcinoma, multiple myeloma, gastrointestinal stromal tumors, mesothelioma, and other solid tumors or other hematological cancers. 62. The method of claim 60 wherein the cancer is small cell lung cancer, non-small cell lung cancer, colorectal cancer, melanoma, renal cell carcinoma, head and neck cancer, Hodgkin's lymphoma, bladder cancer, esophageal carcinoma, gastric carcinoma, ovarian carcinoma, cervical carcinoma, pancreatic carcinoma, prostate carcinoma, breast cancers, urinary carcinoma, brain tumors such as glioblastoma, non-Hodgkin's lymphoma, acute lymphatic leukemia (ALL), chronic lymphatic leukemia (CLL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), hepatocellular carcinoma, multiple myeloma, gastrointestinal stromal tumors, mesothelioma, and other solid tumors or other hematological cancers. 63. The method of claim 61 wherein the cancer is small cell lung cancer, non-small cell lung cancer, colorectal cancer, melanoma, renal cell carcinoma, head and neck cancer, Hodgkin's lymphoma or bladder cancer. 64. The method of claim 62 wherein the cancer is small cell lung cancer, non-small cell lung cancer, colorectal cancer, melanoma, renal cell carcinoma, head and neck cancer, Hodgkin's lymphoma or bladder cancer. 65. A method for treating cancer in a subject in need thereof, comprising administering an effective amount of a compound, according to claim 1, or a pharmaceutically acceptable salt thereof, in combination with the administration of a therapeutically effective amount of one or more immuno-oncology agents. 66. A method for treating cancer in a subject in need thereof, comprising administering an effective amount of a compound, according to claim 24, or a pharmaceutically acceptable salt thereof, in combination with the administration of a therapeutically effective amount of one or more immuno-oncology agents. 67. A method for treating cancer in a subject in need thereof, comprising administering an effective amount of a compound, according to claim 44, or a pharmaceutically acceptable salt thereof, in combination with the administration of a therapeutically effective amount of one or more immuno-oncology agents. 68. The method of claim 65 wherein the immuno-oncology agent is ipilimumab. 69. The method of claim 66 wherein the immuno-oncology agent is ipilimumab. 70. The method of claim 68, wherein the immune-oncology agent is a PD-L1 antagonist.

Details for Patent 10,519,187

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bristol-myers Squibb Company	YERVOY	ipilimumab	Injection	125377	03/25/2011		2038-02-13